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Abstract 
Cis-diamminedichloroplatinum (II) (cisplatin or CDDP) is the first platinum based 
chemotherapy drug used for treating various types of cancers. It is discovered that the 
combination of cisplatin with electron donors can enhance the efficacy of the therapy, 
due to a unique electron transfer mechanism. Deoxyribonucleic acid (DNA) damage is 
a main step of the mechanism of this anticancer drug, which can be effectively detected 
by electrochemical methods. Carbon nanomaterials (CNMs) are electron-rich materials 
with abundant π electrons in their structure. With suitable functionalization, CNMs can 
become biocompatible and act as suitable electron donors to boost the cisplatin 
efficiency. 
Here, we designed two electrochemical methods to detect DNA damage 
respectively using the redox signal of DNA bases, and an indicator species along with 
a single-stranded DNA modified gold electrode (ssDNA-AuE). In the first method, the 
oxidation signal of Deoxyguanosine monophosphate (dGMP) was characterized and 
chosen as an indicator for the study of DNA base damage. Decreased dGMP oxidation 
signal was observed after the dGMP was treated by cisplatin, which suggested the 
binding of cisplatin on guanine (G) base. However, when dGMP was treated by 
cisplatin in combination with N,N,N',N'-Tetramethyl-p-phenylenediamine (TMPD), no 
enhanced effect was observed probably due to the autoionization of TMPD in aqueous 
solutions. In the second method, the ssDNA-AuE was prepared through gold (Au)-thiol 
chemistry, and characterized using a redox pair, ferricyanide/ferrocyanide 
([Fe(CN)6]
3−/[Fe(CN)6]
4-). Lower current response of [Fe(CN)6]
3−/[Fe(CN)6]
4- was 
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observed at the ssDNA-AuE compared with the bare Au electrode, due to the repulsive 
force between this redox pair and the DNA strands on the electrode surface. After the 
ssDNA-AuE was treated by either cisplatin alone or cisplatin in combination with 
TMPD, the redox signal of [Fe(CN)6]
3−/[Fe(CN)6]
4− increased at the treated ssDNA-
AuE, indicating the interaction between DNA strand and cisplatin. We also discovered 
that both cisplatin binding and DNA strands break contributed to the recovered 
[Fe(CN)6]
3−/[Fe(CN)6]
4− signal using elementary analysis. In addition, stronger 
[Fe(CN)6]
3−/[Fe(CN)6]
4− signal was recovered on the ssDNA-AuE treated by the 
combination of cisplatin and TMPD than that treated by cisplatin only, showing that 
this method is sensitive enough to detect the enhanced effect caused by electron donors.  
After the establishment of the detection methods, they was applied to monitor the 
combination effect of cisplatin and CNMs. Briefly, reduced graphene oxide (rGO) was 
synthesized through the modified Hummer’s method followed by hydrazine reduction. 
After grafting Polyethylene glycol (PEG) on the rGO structure, the effect of PEG-rGO 
on the interaction of cisplatin and DNA was studied using the two designed 
electrochemical methods in this project and Clonogenic assay. However, all results 
show that the PEG-rGO has no noticeable effect on improving cisplatin efficiency. 
Therefore future work is needed to design an effective graphene based electron donor.  
Our work suggests that the electrochemical method is a powerful tool for studying 
DNA damage, and can be applied to study the cisplatin and DNA interaction.  
.  
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Chapter 1 
Introduction 
Cis-diamminedichloroplatinum (II) (cisplatin or CDDP) is the first platinum based 
chemotherapy drug used for treating various types of cancers1–3. However, the 
treatment based on cisplatin is limited by the serious side effects and cell resistance4,5. 
To circumvent the drawbacks of cisplatin, over three thousands of cisplatin analogues 
were designed based on the traditional hydrolysis mechanism. However, only 
oxaliplatin and carboplatin was approved by FDA6,7. This fact suggests that there is 
another molecular mechanism governing the toxicity of cisplatin. Recently, it was 
discovered that the combination therapy of cisplatin with electron donors dramatically 
enhanced the cancer cell killing, compared with the treatment of cisplatin only8,9. This 
amazing discovery supported a new cisplatin cytotoxicity mechanism proposed 
recently10 and opened a new gate for us to design better platinum based chemotherapy.  
Carbon nanomaterials (CNMs) such as carbon nanotube (CNT), graphene and 
their derivatives are expected to exhibit strong electron donating capability due to the 
their similar unique electronic structure.11,12. After suitable functionalization, carbon 
nanomaterials can become biocompatible and gain the ability to target cancer cells, 
achieving the targeted killing effect13.  
Electrochemical study of nucleic acid is a booming area in the past two decades. 
The recent research on Deoxyribonucleic acid (DNA) electrochemical study suggests 
that the electrochemical method is a powerful tool for the detection of DNA damage14,15.  
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1.1 Cisplatin 
1.1.1 Hydrolysis mechanism of cisplatin 
Hydrolysis of cisplatin is long believed the key activation process before the 
formation of the harmful cisplatin-DNA adducts1. Figure 1.1 shows that cisplatin can 
be intracellularly activated by the leaving of its single or double leaving groups, the 
chloride, then binding onto DNA and forming the DNA adduct, thereby killing the cells. 
 
Figure 1.1: Scheme of hydrolysis of cisplatin. 
Based on this mechanism, over three thousands of cisplatin analogues have been 
designed in order to relieve the side effects, such as nephrotoxicity, emetogenesis and 
neurotoxicity16 and to broaden the treated cancer types. However, few of them entered 
the clinical trials and only oxaliplatin and carboplatin were approved by FDA6,7. So this 
discouraging fact suggests that there might be another molecular mechanism governing 
the toxicity of cisplatin. And that is the electron transfer mechanism. 
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1.1.2 Electron transfer mechanism of cisplatin 
Recently, Lu and his coworkers discovered that the combination of cisplatin and 
an electron donor dramatically improved the efficiency of cisplatin8,9. This cheering 
discovery is based on a unique electron transfer mechanism observed by the 
femtosecond time-resolved laser spectroscopy10.  
This unique electron transfer mechanism can be expressed by the following 
reaction equations: 
X+ PtCl2(NH3)2 = [PtCl2(NH3)2]*
-+ X+ = X++ Pt(NH)2Cl·+ Cl
-         (1.1) 
X+ Pt(NH)2Cl· = [PtCl(NH3)2]*
-+ X+ = X++ Pt(NH)2·+ Cl
-            (1.2) 
X = G>A>>C, T 
Instead of undergoing a hydrolysis process, cisplatin gains an electron directly 
from DNA bases (especially guanine (G)), forming an excited cisplatin star which 
quickly dissociate into a cisplatin radical and a chloride anion. This radical with one 
free electron is super reactive with another DNA base, leading to the leaving of the 
other chloride and the binding of Pt(NH)2: to DNA bases.  
The electron transfer mechanism not only supplied a new understanding of the 
molecular mechanism of cisplatin, but also unraveled the long existed mystery why 
cisplatin prefer to bind on two neighboring G bases, which has the highest electron 
donating capability among the four types of DNA bases. 
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1.1.3 Electron transfer mechanism based cisplatin combination 
chemotherapy 
Based on the electron transfer mechanism, Lu and his coworkers predicted that 
combining a biological electron donor with cisplatin can greatly enhance the 
chemotherapeutic efficacy of cisplatin. So a combination therapy using N,N,N',N'-
Tetramethyl-p-phenylenediamine (TMPD), a well-known electron donor due to its 
aromatic amines structure, and cisplatin was designed9. In the combination therapy of 
cisplatin and TMPD, the following reaction is expected to take place: 
TMPD + CDDP → TMPD+: Cl- + Pt(NH3)2CI·               (1.3) 
Briefly, the TMPD molecule can act as an electron donor to give one electron to 
cisplatin, thereby forming the super reactive cisplatin radical, which can lead to the 
DNA strand breaks and therefore cell death.  
In order to verify the electron transfer reaction between TMPD and cisplatin, 
fluorescence and Ultraviolet–visible (UV-vis) absorption spectroscopic measurements 
were performed. For both measurements, the characteristic signal belonging to TMPD+ 
was observed, suggesting the occurrence of the electron transfer reaction.  
In addition, DNA damage assay were carried out to study the actual efficacy of 
this type of combination therapy. In the gel electrophoresis assay, it is shown that 
cisplatin can directly induce DNA double strand break and the combination of cisplatin 
and TMPD greatly increased the yield of this kind of break by a factor of 3.5. This result 
provided a strong evidence that the radical produced in the dissociative electron transfer 
reaction shown in Eq. 3.1 greatly enhanced the DNA double strand break. 
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What is even more interesting is that this type of combination chemotherapy not 
only improved the cell killing, but also overcame the resistance of cisplatin-resistant 
cell lines, such as NIH:OVCAR-3 cells. NIH:OVCAR-3 is a cell line with high cisplatin 
resistance, showing a 40% cell viability percentage even after 250 uM cisplatin 
treatment for 24 hours. However, almost 90% cell killing was achieved by combining 
100 uM TMPD and 100 uM cisplatin to treat the cells for 24 hours. And almost 100% 
NIH:OVCAR-3 cells were killed, when the concentration of cisplatin reached 150 uM. 
In conclusion, this electron transfer mechanism based combination chemotherapy 
opened a new gate to design the platinum based chemotherapy, and provided a great 
opportunity to improve the treatment of many types of cancers. 
1.2  Carbon nanomaterials 
CNMs, including fullerene, carbon nanotubes (CNTs) and graphene, have 
attracted broad attentions due to their unique physical and chemical properties17. Figure 
1.2 shows the structures of these three basic carbon nanomaterials. 
As the fundamental structure of all the carbon nanomaterials, graphene became 
the most popular material since the first day it was discovered.  
 
Figure 1.2: Structures of fullerene, carbon nanotube and graphene from left to right 
respectively. 
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1.2.1 Electron donating capability of graphene.  
Graphene is a carbon allotrope made of bonded carbon atoms organized into a 
planer hexagonal lattice. The hybridization type of carbon in graphene is sp2, leaving 
an electron in the unhybridized p orbital to form a delocalized π (pi) bond. As a result, 
graphene has very unique electronic property and has the potential to act as either an 
electron donor or an acceptor11,12.  
Graphene is a unique zero band gap semiconductor due to the touch of its conduct 
and valence band at the Brillouin zone corners. The electron transfer between graphene 
and other molecules depends on the difference in the electronic chemical potential 
between them18. Briefly, whether graphene is an acceptor or donor is determined by the 
relative positions of graphene’s Fermi level and the highest occupied molecular orbital 
(HOMO) and the lowest unoccupied molecular orbital (LUMO) of the interactant. 
Figure 1.3 shows when the LUMO of an interactant has lower energy level compared 
with the Fermi level of graphene, the electron will transfer from graphene to the 
interactant and forming a p-type doping, while the electron will transfer from the 
interactant to graphene when the interactant’s HOMO energy is higher than the Fermi 
level of graphene.  
The electron transfer between graphene and other molecules has been well studied 
by the surface doping of graphene19–21. It was reported that NO2 can greatly decrease 
the resistance of graphene due to the electron transfer between graphene and NO2
22. 
The electron affinity of NO2 is calculated to be about 0.4 eV below the Fermi level of 
graphene, determining that NO2 is a very strong electron acceptor when interacting with 
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graphene. As a result, a high density of electrons is transferred from graphene to NO2, 
leaving the graphene as a p-doped semiconductor with low resistance.  
 
 
Figure 1.3: The scheme of the relative position of graphene’s Fermi level and the 
LUMO and HOMO energy level of interactants.  
Molecules with electron-withdrawing groups can also have electron transfer 
reaction with graphene. Rao et al. reported that nitrobenzene and tetracyanoethylene 
(TCNE) successfully produced the p-doping graphene evidenced by Raman spectra23–
26. Chen et al. demonstrated that, by using synchrotron-based high-resolution 
photoemission spectroscopy, the electron transfer from epitaxial graphene (EG) to 
Tetrafluoro-tetracyanoquinodimethane was observed21.  
Even though the electron transfer reaction between cisplatin and graphene has 
never been studied, the interaction between graphene and platinum (Pt) was studied 
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before. Giovannetti et al. showed, by using density functional theory, that electrons 
transferred from graphene to Pt due to the difference in graphene’ fermi level and Pt’s 
electron affinity27. Considering the valence of Pt in cisplatin is 2+, it is reasonable to 
expect that electrons transfer from graphene to this long-lived drug.  
1.2.2 Synthesis of graphene 
The common used synthesis method of graphene is the exfoliation and cleavage 
of graphite or thermal chemical vapor deposition28–31. The modified Hummer’s method 
is an efficient way to produce graphene oxide (GO) through exfoliation and sonication. 
The GO synthesized through this method has very good solubility in water and some 
other solvents. Due to its low cost, convenience, high productivity and some other 
advantages, the modified Hummer’s method is the most commonly used method to get 
graphene in research labs. Figure 1.4 shows how the GO is synthesized from graphite 
step by step through the modified Hummer’s method. 
 
Figure 1.4: scheme of the modified Hummer’s method for synthesizing GO. 
However, the electronic property of graphene is damaged by the high density of 
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defects caused during the harsh oxidation process. So reduction treatments are usually 
needed, in order to recover the unique structure of graphene. 
The main GO reduction strategies include thermal reduction and chemical 
reduction32–35. It was reported that GO can be reduced at high temperature, namely 
thermal annealing reduction35. However this reduction strategy is not suitable to be used 
for liquid sample because of the high temperature needed, potentially causing extra 
inconvenience to our future electron transfer test, so chemical reduction could be a 
better alternative for this project.  
Usually, chemical reduction can be realized under some moderate environment, 
such as at room temperature. It makes the reduction in aqueous solution possible. 
Stankovich et al. initiated an easy chemical reduction method for GO using 
hydrazine33,34. The success of the reduction was confirmed by the C/O ratio in the 
structure and Raman spectroscopy. However the aggregation of graphene nanosheets 
was observed after the reduction by hydrazine or its derivatives. This irreversible 
aggregation after reduction restricted the application of graphene in many areas, such 
as the biological area in this project.   
So in order to make graphene suitable for biological application, the priority is 
improving the biocompatibility and solubility of graphene. Dan et al. demonstrated that 
graphene can disperse well in water by controlling the hydrazine reduction conditions36. 
In their method, the hydroxyl and epoxy groups, but not carboxylic acid groups on the 
GO will be reduced by hydrazine under the conditions they described. Due to the 
electrostatic interaction between the negative charges on carboxylic acid groups, the 
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graphene nanosheets can disperse well in water without aggregation. However, the 
stability of this type of rGO is still not enough for biological application, because the 
high salt condition can disrupt the electrostatic interaction, and cause the aggregation 
again. As a result, further functionalization to the rGO is still necessary.  
1.2.3 Functionalization of graphene  
The main purposes of the functionalization in this project include improving 
graphene’s biocompatibility and solubility as well as modifying graphene into a suitable 
electron donor. Until now, the most popular functionalization method to make graphene 
biocompatible is PEGylation13,37–40.  
The following are several properties of Polyethylene glycol (PEG) making it 
especially eligible in various biological and pharmaceutical applications 
 Non-toxic and non-immunogenic – greatly enhance the biocompatibility of the 
functionalized molecules without interfering with cellular functions.  
 Hydrophilic (aqueous-soluble) – PEGylation endows the functionalized 
molecules with perfect water solubility.  
 Highly flexible – provides for surface treatment or bioconjugation without steric 
hindrance 
The main strategies to link PEG on graphene include covalent method and non-
covalent method41. Non-covalent method usually links PEG on graphene by the 
hydrophobic interaction. For example, graphene can be functionalized by phospholipid-
PEG. For covalent method, a covalent bond is usually formed between PEG and 
graphene. The covalent method usually adopts conventional carbodiimide chemistry to 
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form the covalent bond. Zhuang et al. reported that amine-terminated branched PEG 
(six armed-PEG-NH2) can be covalently conjugated on the carboxyl groups on GO 
surface under the help of N-(3-dimethylaminopropyl-N’-ethylcarbodiimide) 
hydrochloride (EDC)41. Michael et al. demonstrated that amine terminated linear PEG 
can be successfully grafted on GO using EDC-NHS as the catalyst42.  
Considering that the appearance of carboxyl groups and amine groups is the only 
demand for carbodiimide chemistry, the rGO prepared in Dan’s protocol turns out to be 
a very suitable starting material for later PEGylation, because the electronic property 
was recovered and the required carboxyl groups was kept at the same time. Therefore 
this modified hydrazine reduction method together with the covalent PEG 
functionalization provides a suitable approach to produce a type of biocompatible 
reduced graphene for the study of the electron transfer reaction between graphene and 
cisplatin.  
1.3 DNA damage study 
Because DNA is the molecule which carries most genetic information in all living 
organisms, its integrity and stability is very important. However, DNA is sensitive to 
many factors and can be damaged because of either intrinsic or extrinsic reasons, 
leading to mutations and diseases like cancer. Detection of damage has important 
application in lots of areas such as theranostics, biosensor, targeted drug delivery and 
biomedicine. So developing economic and effective technique to detect DNA damage 
is necessary. The following content will briefly introduce several common DNA 
damage detection methods and the relatively new electrochemical method.  
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1.3.1 Common DNA damage detection methods 
Electrophoresis: gel electrophoresis is a routine technique to identify, quantify 
and purify nucleic acid fragments43,44. Due to the negatively charged phosphate 
backbone in DNA structure, nucleic acid molecules can be moved by applying electric 
field through a matrix of agarose or other substances. For DNA fragment, the larger the 
size is, the more slowly it can move through the matrix, while the smaller the size is, 
the faster the fragment can move. As a result, the information about DNA structure 
change can be confirmed based on the position of DNA fragments in the gel. In the past 
decades, some improvements were made to gel electrophoresis technique, such as 
Single cell electrophoresis (SCGE)45, pulsed field gel electrophoresis (PFGE)46, 
Denaturing gradient gel electrophoresis (DGGE)47, etc. 
Although gel electrophoresis is relatively simple to perform and inexpensive, it 
does have some disadvantages such as poor sensitivity and low accuracy, as well as 
toxicity due to some DNA visualizing dyes such as Ethidium Bromide, which is a 
known carcinogen48. 
Mass spectrometry: the most outstanding feature of this technique is that MS can 
provide structural information about DNA damage. Coupled with gas chromatography 
(GC) or liquid chromatography (LC), some complex mixtures can be easily detected49–
51. It was reported that, by using GC-MS technique, a variety of DNA damage products 
can be measured including sugar backbone, DNA bases and DNA-protein adducts52. 
Dizdaroglu demonstrated that a series of products from oxidatively damaged DNA 
bases could be measured by GC-MS successfully53. The quantification of DNA base 
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damage was achieved by adding stable isotope-labeled analogs of DNA bases as an 
internal standard54. However, artifacts may occur in this technique due to the high 
separating temperature. To reduce the artifacts, LC-MS technique was employed to  
detect the modified base products55. But the sensitivity of LC-MS is not as good as GC-
MS. Considering the economy and efficiency, this technique is not an ideal method for 
DNA damage detection.  
Terminal deoxyribonucleotidyl transferase mediated deoxyuridine 
triphosphate nick end labeling (TUNEL assay): Upon DNA fragmentation or 
breakage, the 3'-OH termini of DNA strands become free. This free termini will be 
catalytically labelled by dUTPs, which is secondarily labelled with markers such as a 
fluorophore, under the help from terminal deoxyribonucleotidyl transferase (TdT). 
Based on the signal from the marker, the DNA strand break can be detected and 
quantitated. Since Gavrieli et al. firstly reported this method in 1992, this method has 
been improved a lot to increase its accuracy56,57. The disadvantages of TUNEL assay 
include the tedious proceeding steps involved and the relatively high cost.  
1.3.2 Electrochemical DNA damage study 
The electrochemical study of DNA is a popular area in the past two decades15. 
According to statistics, an average of ~10 papers about DNA related electrochemical 
study were published per year between 1960~1989, while almost ~760 papers were 
published in 2010 alone. For the past few years, the number of publications about DNA 
related electrochemical study has been experiencing an exponential growth. So the 
electrochemical study of DNA will be a very popular and promising area in the future. 
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1.3.2.1 Electrochemistry of DNA bases 
As early as seventy years ago, the electroactivity of adenine (A) has been shown 
through Polarographic reduction by Heath58. Further studies revealed both A and 
cytosine (C) and their nucleosides and nucleotides can be reduced with half-wave 
potentials at -1.33V for A and -1.44V for C (vs SCE)59–62. However, within the mercury 
electrode potential window, reduction of Uracil (U) and Thymine (T) was not observed. 
The reduction signal of G can only be observed when the potential almost reach the 
electrolyte discharge potential63. From these studies, it is shown that the reduction 
signal of most DNA bases was at very negative potential, and there was even no 
reduction of U and T within the mercury potential window. Along with the poisonous 
property of mercury, it turned out that using the reduction signal is not a convenient 
method to get DNA bases information. 
For the oxidation of DNA bases, nucleotides, or nucleosides, carbon based 
electrodes are most frequently employed. Compared with Pyrimidine bases, Purine 
bases have lower oxidation potential, with G being the easiest one to be oxidized. Glenn 
et al. demonstrated, with a pyrolytic graphite electrode, that the oxidation of G went 
through a 4-electron process, with the –N(7)=C(8)H- bond oxidized initially and 
followed by the oxidation of the –C(4)=C(5)- bond, while the oxidation of adenine went 
through a 6-electron process with the similar initial step64,65. Oliveira et al. reported, at 
the glassy carbon electrode (GCE), that the oxidation peaks of G, A, T, C were 
characterized at +0.70 V, +0.96 V, +1.16V and +1.31V (vs Ag/AgCl) respectively66. 
Similar results were obtained by Stempkowska at the paste carbon electrode, showing 
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the oxidation peaks of Guanosine monophosphate (GMP), adenosine monophosphate 
(AMP), thymidine monophosphate (TMP) and cytosine monophosphate (CMP) at 
+1.00 V, +1.28 V, 1.47 V and 1.53 V (vs Ag/AgCl) respectively67.  
DNA base damage can be induced by oxidative agents, reductive agents and 
genotoxic agents. Currently, the DNA base damage is usually detected using optical 
method coupled with some separation techniques, such as liquid chromatography, 
making the detection laborious and expensive68,69. Alternatively electrochemical 
methods can be applied to detect base damage induced change in intrinsic redox signals 
such as the reduction of the oxidation peak. G is the most common target for a broad 
range of these base reactive agents, and also gives the easiest measurable signal at 
carbon based electrodes, making the electrochemical study of G and its nucleotide and 
nucleoside a feasible approach to study DNA base damage. Up to now, many base 
targeting agents have been studied using DNA base electrochemistry, such as hydrazine 
derivatives, Adriamycin and quercetin70–72. For platinum based genotoxic agents, 
Brabec successfully detected the G oxidation peak decrease by using differential pulse 
voltammetry (DPV) after treating DNA with a platinum based anticancer drug, 
[Pt(dien)(H2O)]
2+, 73.  
1.3.2.2 DNA modified electrode 
The modification of electrode was studied as early as 20 years ago. Kelly et al. 
first reported that carbon glassy electrode can be modified by DNA oligonucleotides, 
and used for the detection of DNA hybridization74. After that, more DNA modified 
electrodes were designed for the study of DNA hybridization, DNA sequencing and 
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DNA damage75–78. Due to the stability and convenience of thiol-gold (Au) chemistry, 
DNA modified Au electrode are the most common choice at present79,80.  
DNA modified electrodes can be used for two types of measurements depending 
on the origin of the electrochemical signal. The first measures the intrinsic redox signal 
of DNA, for example, the oxidation signal of G. The second measures the redox signal 
of other indicators, such as methylene blue, ferrocene, hexaamineruthenium 
([Ru(NH3)6]
3+), etc. 
It is well known that a DNA strand bears negative charges due to the phosphate 
groups in its structure. After attaching DNA strands to an electrode, the negatively 
charged electrode surface can be either repulsive or attractive towards negatively 
charged or positively charged redox indicators respectively. As a result, the 
concentration of the redox indicator at the surface of a DNA modified electrode will be 
different compared with that at a bare electrode, leading to different current response. 
Li et al. reported that DNA modified Au electrodes can pre-concentrate [Ru(NH3)6]
3+ 
at the electrode surface, giving higher current intensity compared with bare Au 
electrodes81. Miranda et al. demonstrated that the negatively charged redox pair 
ferricyanide/ferrocyanide ([Fe(CN)6]
3−/[Fe(CN)6]
4−) gives lower redox current on a 
DNA modified electrode than that on a bare Au electrode in its CV curves82.  
Initially, DNA modified electrodes were mainly used for DNA hybridization 
detection. Later on, these devices were used for the detection of DNA damage including 
DNA strand break and single base mismatch. Labuda et al. demonstrated a method for 
the detection of DNA double strand disruption using redox species binding specifically 
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to double-stranded DNA and producing a redox signal at carbon electrodes83–85. Upon 
DNA degradation, the redox signal decreased because of its lower affinity to single-
stranded DNA (ssDNA). Jacqueline et al. successfully monitored the kinetics of DNA 
restriction caused by a DNA restricting enzyme, R.PvuII, using the signal of some redox 
species linked on DNA strands86. When DNA was restricted by the enzyme, the redox 
species left the electrode surface and the redox signal were lost. 
In summary, the electrochemical study of DNA is a very powerful tool to detect 
DNA damage. The advantage of electrochemical methods include low cost, high 
reliability, high speed and simplicity.  
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Chapter 2 
Design of electrochemical detection methods for 
detecting the cisplatin and DNA interaction 
2.1 Introduction 
As it was mentioned in Chapter 1, cisplatin can undergo electron transfer reaction 
with DNA bases and therefore forming the cisplatin-DNA adducts. By adding 
biological electron donors, more DNA double strand break was found and the cell 
killing efficiency was enhanced. So we can utilize the intrinsic oxidation signal of G to 
study the interaction between cisplatin and DNA base. The reason we use G is that it 
has the highest reactivity to cisplatin among all DNA bases, and meanwhile has the 
lowest oxidation potential, effectively avoiding the high background current at high 
potential range. In addition, Au electrodes can be modified by ssDNA and the 
[Fe(CN)6]
3−/[Fe(CN)6]
4−
 redox pair can be used as an indicator to show the interaction 
between cisplatin and the DNA strands on the electrode surface. Due to the electrostatic 
repulsion between ssDNA and this negatively charged redox pair, the intensity of the 
redox current is expected to decrease greatly after DNA modification. After the DNA 
strands on electrode surface was treated by cisplatin, both cisplatin binding and DNA 
strand break are expected to introduce changes to the redox current.  
In this chapter, two electrochemical methods adopting intrinsic DNA redox signal 
and extrinsic species redox signal will be designed to monitor the DNA damage caused 
by cisplatin and the enhanced DNA damage caused by combining cisplatin and electron 
donors. 
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2.2 Electrochemistry of guanine 
2.2.1 Introduction 
The electrochemical study of G has been performed at carbon based electrodes, 
Au electrodes, platinum electrodes, mercury electrodes previously64. The most 
distinguishable signal is given by carbon based electrodes including pyrolytic graphite, 
glassy carbon, carbon paste and some other modified carbon electrodes. Most of these 
studies were done by the two most commonly used electrochemical methods, DPV and 
cyclic voltammetry (CV), and the later method is the one used in this project. 
For CV, a three electrodes system, including working, reference electrode and 
counter electrodes87, is used. A triangle shape potential is applied to the working 
electrode (as shown in Figure 2.1) and facilitate the electron transfer between the redox 
species and the electrode surface. When the applied potential on working electrode is 
more positive than the standard potential of the redox species in solution, the relative 
species will be oxidized, thereby producing a cathodic current (electrons going from 
solution to electrode). Similarly, as the potential scans back, an anodic current will be 
produced (electrons going from electrode to solution).  
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Figure 2.1. A CV potential waveform with switching potentials. 
 By IUPAC convention, anodic currents are positive and cathodic currents 
negative, so a typical CV curve of a reversible reaction looks like the one shown in 
Figure 2.2a. For an irreversible electrochemical reaction, due to the slow charge transfer 
or unstable electrochemically produced products, the CV curve looks like the one 
shown in Figure 2.2b.  
 
Figure 2.2: (a) Typical CV curve of a reversible electrochemical reaction. (b) Typical 
CV curve of an irreversible electrochemical reaction. In this case, the product after 
oxidation is unstable so there is only anodic current but not cathodic current. 
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In both situations, the peak current has a linear relationship with the analyte 
concentration as expressed in Equation 2.1a and 2.1b87. 
Reversible reaction:   ip = (2.69x10
5)n3/2ACD1/2v1/2                       (2.1a) 
Irreversible reaction:  ip = (2.99x10
5)n(αna)1/2ACD1/2v1/2                   (2.1b) 
Where ip is the peak current, n is the number of electrons transferred in the 
electrochemical reaction, A is the area of electrode, D is the diffusion coefficient of the 
species, v is the scan rate and C is the concentration of the redox species. 
2.2.2 Materials and Methods 
Chemicals and reagents: Deoxyguanosine monophosphate (dGMP) (D9500, 
MW: 347.22), cisplatin (P4394, MW: 300.05) and TMPD (T7394, MW: 164.25) were 
purchased from Sigma-Aldrich and used without further purification. 0.1 M stock 
dGMP solution and 4 mM stock cisplatin solutions were prepared using Milli-Q water. 
0.1 M TMPD stock solution was prepared using HPLC degree ethanol (34852) 
purchased from Sigma-Aldrich. 
Characterization of dGMP oxidation signal: a series of dGMP solutions with 
concentrations of 0 uM (as the background current) 100 uM, 300 uM, 500 uM and 1 
mM were prepared by using the stock dGMP solution and 0.5 M pH 5.0 acetate buffer. 
Before tests, the GCE (CH Instruments, Inc. CHI104) was polished using1 um, 0.3 um 
and 0.05 um alumina in sequence (the electrode was rinsed carefully between each 
polish) and softly sonicated in a 30 % ethanol solution for 5 mins to clean the electrode 
surface. To improve the reproducibility, the polished GCE was electrochemically 
activated by being scanned in a 0.5 M H2SO4 solution from -0.5 V to 1.5 V at 0.1 V/s 
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scan rate until stable CV curves were obtained. CV curves of the prepared series of 
dGMP solutions were recorded using a CHI650 potentiostat through a three electrodes 
system (Figure 2.3a) including the as-treated GCE (working electrode), a Sliver/Sliver 
chloride (Ag/AgCl) (reference electrode) and a Pt wire electrode (counter electrode).  
Interaction between cisplatin and DNA base: a mixture of 500 uM cisplatin and 
500 uM dGMP solution was prepared by using the stock solutions and 0.5 M acetate 
buffer at pH 5.0. Pure 500 uM cisplatin solution was prepared by using the same stock 
cisplatin solution and acetate buffer, in order to test the background current. CV curves 
of both solutions after 0, 5, 10, 24 and 48 hours incubation at room temperature were 
recorded using the same electrodes and potentiostat mentioned before.  
Effect of TMPD on interaction between cisplatin and DNA base: solutions of 
500 uM dGMP and 1 mM TMPD mixed with 50, 100, 200, 300 and 500 uM cisplatin 
respectively were prepared by using the stock solutions and 0.5 M acetate buffer at pH 
5.0. Solutions of 1 mM TMPD mixed with 50, 100, 200, 300 and 500 uM cisplatin 
respectively were prepared by using the same stock solutions and acetate buffer, in 
order to gain the background currents. CV curves of solutions with 500 uM cisplatin 
with and without TMPD were recorded after 0, 5, 10, 24 and 48 hours incubation using 
the same electrode and potentiostat mentioned before. CV curves of all the other 
solutions were recorded after 0 and 24 hours using the same electrode and potentiostat.  
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2.2.3 Results and Discussion 
The CV curves of dGMP at different concentrations were shown in Figure 2.3b. 
Part of the oxidation signal of dGMP overlapped with the background current from the 
oxidation of water, causing problems to correctly identify the dGMP oxidation peak. 
The background-subtracted CV curves of dGMP at different concentrations were 
produced after subtracting the background current as shown in Figure 2.3c. It turned 
out that dGMP only had one oxidation peak around 1.1 V, but no reduction peak was 
observed, demonstrating that an irreversible reaction due to the unstable oxidized 
product, which is consistent with the previous literature67. In addition, a perfect linear 
relationship was found between the oxidation peak current intensity and the dGMP 
concentration as shown in Figure. 2.3d. In conclusion, the dGMP oxidation peak was 
successfully characterized by using the GCE and the CV method described in this 
project.  
 
24 
 
Figure 2.3: (a) The experiment setup for the electrochemical test. (b, c) CV of dGMP 
at different concentration before and after background subtraction. Scan rate: 20 mV/s 
(d) the absolute value of dGMP oxidation peak current versus dGMP concentration, 
the line is a linear fit of the data points.  
Figure 2.4a shows the effect of cisplatin on dGMP oxidation signal. After 5 hours 
incubation, the absolute value of dGMP oxidation peak decreased from 10.42 to 9.614 
uA. After 48 hours incubation, the absolute value of dGMP oxidation peak decreased 
to 5.2 uA, showing that over half of the dGMP signal was reduced by cisplatin. Brabec 
demonstrated that upon the binding of cisplatin on G base, the oxidation current will 
decrease to 80 times lower than the G base itself73. So the decrease of the dGMP 
oxidation signal in our experiment can be attributed to the binding of cisplatin on this 
G base containing nucleotide. By analyzing the degree of this oxidation peak decrease, 
the adduction of cisplatin on dGMP can be monitored. 
Furthermore, the effect of the electron donor, TMPD, on the interaction between 
cisplatin and dGMP was tested, as shown in Figure 2.4 b. The CV curves of the solution 
containing 500 uM dGMP and 500 uM cisplatin plus 1mM TMPD at various time points 
showed similar decrease in current intensity. To show the effect of TMPD on dGMP 
damage induced by cisplatin, the dGMP oxidation peak values in both situations (with 
and without TMPD) versus incubation time was plotted, as shown in Figure 2.4c. 
However, TMPD only slightly increased the initial absolute value of dGMP oxidation 
peak from 10.42 uA to 12.04 uA rather than leading to a more dramatic decrease of 
dGMP oxidation peak. After normalization, the changes of normalized peak value over 
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time are almost identical regardless of the presence TMPD, (Figure 2.4d).  
 
Figure 2.4. Background subtracted CV curves of dGMP mixed with (a) 500 uM CDDP 
and (b) 500 uM CDDP+1mM TMPD after 0,5,10, 24 and 48 hours, Scan rate: 20 mV/s 
(c) absolute and (d) normalized oxidation peak current intensities of 500 uM dGMP 
mixed with 500 uM CDDP (■), 500 uM CDDP+1 mM TMPD(●) over time.  
 
Futhermore, 500 uM dGMP was mixed with a series of lower concentrations of 
cisplatin with and without TMPD and the CV curves of dGMP were recorded. Figure 
2.5 shows the dGMP oxidation peak percentage value after 24 hours treatment by 
cisplatin only, and cisplatin in combination with TMPD. At all cisplatin concentrations, 
TMPD didn’t show any noticeable effect. 
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Figure 2.5: Percentage peak value of 500 uM dGMP mixed with various 
concentrations of CDDP only (■), various concentrations of CDDP in combination 
with 1 mM TMPD (■) after 24 hours reaction (the initial peak value is the peak value 
after 0 hours reaction). Scan rate: 20 mV/s  
TMPD is a very reactive compound and reported to be autoionized easily even in 
water due to its low ionization potential88,89. In our experiment, the color change of the 
water solutions containing TMPD was also observed after a couple hours of incubation. 
This autoionization could be the reason why we didn’t see the enhanced dGMP damage 
in this experiment. However, both the DNA strand break study and cell viability test 
conducted in Lu’s work were also in water environment, and the enhanced effect caused 
by TMPD (same cisplatin/TMPD ratio as used in this project) was able to be observed 
in their experiments9. Therefore, further investigation is needed to confirm whether the 
autoionization of TMPD in water is the reason for the lack of enhanced cisplatin 
adduction on the G base observed in this set of experiment.  
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2.2.4 Conclusion 
In summary, the dGMP oxidation peak was characterized and investigated, at GCE 
by using CV method. The interaction between dGMP and cisplatin was confirmed by 
the decrease of the dGMP oxidation peak current intensity at various time points. The 
effect of TMPD on the interaction between dGMP and cisplatin was investigated by 
incubating these three substances together. However, the combination of cisplatin and 
TMPD didn’t lead to faster or more pronounced decrease in the dGMP oxidation peak 
compared with cisplatin itself. TMPD is known to undergo autoionization when 
interacting with water, even though enhanced DNA double strand break and cell killing 
efficiency were observed in aqueous solutions previously. Future experiments with 
alternate designs, for example, by using a non-aqueous electrolyte to avoid the 
autoionization of TMPD or using some other electron donors which are stable in water, 
might be needed to observe the combinational effects on DNA damage. 
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2.3 DNA modified Au electrode for DNA damage 
study 
2.3.1 Introduction 
Au surfaces can be easily modified using thiol terminated compounds via the 
robust Au-sulfur bond. This Au modification strategy is used in many areas including 
surface science, biotechnology, inorganic chemistry, and has potential applications in 
biosensor, drug delivery, Au nanoparticle modification, etc90–92. Therefore, thiol 
terminated DNA strand can be a feasible approach to make the DNA modified Au 
electrode. The success of the modification can be verified by using electrochemical 
analysis and elementary analysis techniques such as X-ray photoelectron spectroscopy 
(XPS). 
The interaction between cisplatin and DNA can be studied by the change in the 
redox signal of an electroactive pair [Fe(CN)6]
3−/[Fe(CN)6]
4−. As mentioned in Chapter 
1, repulsive force exists between the DNA modified electrode surface and the 
[Fe(CN)6]
3−/[Fe(CN)6]
4−
 redox pair because of the negatively charged DNA phosphate 
backbone. After treated by cisplatin, the DNA strands on the electrode could be 
damaged, so the [Fe(CN)6]
3−/[Fe(CN)6]
4− indicator would give different response. 
Based on the change of [Fe(CN)6]
3−/[Fe(CN)6]
4− signal, the interaction between 
cisplatin and DNA can be studied. 
2.3.2 Materials and Methods 
Chemicals and reagents: DNA oligomer was purchased from Integrated DNA 
Technologies. The DNA sequence is 5’-SH-AAAAAAAAACCCAGGTTCTCT. DNA 
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stock solution of 100 uM was prepared and stored at 20 ℃.6-Mercapto-1-hexanol 
(MCH) was purchased from Sigma-Aldrich. MCH stock solution of 100 mM was 
prepared and stored at room temperature. [Fe(CN)6]
3− was obtained from J. T. Baker 
and a stock solution of 1 M was prepared.  
Modification of Au electrode: Initially, the Au electrode (CH Instruments, Inc. 
CHI101) was treated with the piranha solution for 20 mins to remove the organic 
impurities, followed by rinsing with Milli-Q water. The treated electrode was polished 
afterwards by using 1 um, 0.3 um and 0.05 um alumina in sequence (the electrode was 
rinsed carefully between each polish) and gently sonicated in a 30 % ethanol solution 
for 5 mins. To improve the reproducibility, the clean electrode was electrochemically 
activated by being scanned in a 0.5 M H2SO4 solution from -0.5 V to 1.5 V at 0.1 V/s 
scan rate until stable CV curves were obtained. The as-prepared Au electrode was 
incubated in a 3 uM thiol terminated single-stranded DNA (ss-DNA) solution for 4 
hours, followed by 1 hour 1 mM MCH treatment to remove the unstable linked DNA 
strands out of the electrode surface. The single-stranded modified gold electrode 
(ssDNA-AuE) was kept in water for future use. 
Electrochemistry of ssDNA-AuE: the CV curves of 5 mM 
[Fe(CN)6]
3−/[Fe(CN)6]
4− was recorded by using the bare Au electrode (after the 
standard cleaning process) and the ssDNA-AuE from -0.2 V to 0.6 V (vs Ag/AgCl) 
respectively, with a scan rate 0.01 V/s.  
Study of the interaction cisplatin and DNA strand: 500 uM cisplatin solution 
was prepared by using the stock cisplatin and ethanol. The CV curves of 5 mM 
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[Fe(CN)6]
3−/[Fe(CN)6]
4− was recorded under the same scan condition, by using the 
ssDNA-AuE after 0, 2, 4, 8 and 19 hours treatment in the 500 uM cisplatin solution.   
Effect of TMPD on the interaction between cisplatin and DNA strand: 500 
uM TMPD (as a control) and a mixture of 500 uM cisplatin and 1 mM TMPD solutions 
were prepared by using the stock solutions and ethanol. The CV curves of 5 mM 
[Fe(CN)6]
3−/[Fe(CN)6]
4− was recorded under same scan condition, by using the ssDNA-
AuE after 0, 2, 4, 8 and 19 hours treatment in the prepared solutions.  
Elementary analysis of the DNA modified Au surface: a piece of Au coated 
silicon wafer was prepared (a gift from Prof. Jonathan Baugh’s lab) and used for further 
DNA modification. The prepared Au surface was rinsed with acetone, isopropanol (IPA) 
and Milli-Q water in sequence and blown dried by pure nitrogen gas. The as-treated Au 
surface was modified by using 3 uM thiol terminated ssDNA solution to make the DNA 
modified Au surface. Half of the Au coated silicon wafter was incubated in a 500 uM 
cisplatin solution for 8 hours and rinsed with Milli-Q water for XPS characterization. 
All XPS spectra were acquired by using a Thermo Scientific ESCALAB 250Xi XPS 
spectrometer with a monochromatic Al-Kα X-ray source. High resolution scans were 
acquired for N 1s, P 2p, Au 4f and Pt 4f regions for the DNA functionalized on the Au 
coated silicon wafer. All XPS spectra were analyzed by using the software CasaXPS.  
2.3.3 Results and Discussion 
CV curves of 5 mM [Fe(CN)6]
3−/[Fe(CN)6]
4− were recorded by using the bare Au 
electrode and the ssDNA-AuE respectively (Figure 2.6a). From the CV curve gained at 
bare Au electrode, a reversible reaction, with a redox peaks potential difference (△Ep) 
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74 mV and a oxidation peak current intensity (Ipc) -10.45 uA, was confirmed. Upon the 
modification of DNA on the electrode, the Ipc of [Fe(CN)6]
3−/[Fe(CN)6]
4− greatly 
decreased to -0.6429 uA along with the separation of the △Ep to 499 mV. It is as 
expected because the repulsive force between the DNA strands on the electrode surface 
and [Fe(CN)6]
3−/[Fe(CN)6]
4− pushed the anions away and slowed down the electron 
transfer rate between the two interfaces. So a lower current response of 
[Fe(CN)6]
3−/[Fe(CN)6]
4− was observed. Based on this change, the ssDNA-AuE was 
characterized.  
Figure 2.6b shows the CV curves of [Fe(CN)6]
3−/[Fe(CN)6]
4−
 tested on the ssDNA-
AuE treated by cisplatin only and that treated by cisplatin in combination with TMPD 
after 8 hours. For cisplatin only, the CV curve of [Fe(CN)6]
3−/[Fe(CN)6]
4− shows that 
the Ipc recovered from -0.6364 uA to -6.106 uA and the △Ep decreased from 499 mV 
to 221 mV, indicating that cisplatin partly reduced the repulsive interaction between 
DNA strands and [Fe(CN)6]
3−/[Fe(CN)6]
4−. For the combination of cisplatin and TMPD, 
the CV curve of [Fe(CN)6]
3−/[Fe(CN)6]
4− shows that the Ipc recovered from -0.6429 uA 
to -7.499 uA along with the △Ep narrowing from 495 mV to 169 mV, showing that a 
higher degree of changes occurred to the DNA strands on the Au electrode than that of 
cisplatin only. Figure 2.6c and Figure 2.6d respectively shows the trends of the Ipc and 
the △Ep of [Fe(CN)6]3−/[Fe(CN)6]4− over time after the ssDNA-AuE was treated by 
cisplatin only, and cisplatin in combination with TMPD. In both figures, it is shown 
that combination of cisplatin and TMPD greatly increased the effect of cisplatin on 
DNA strand, leading to a stronger recovery of the [Fe(CN)6]
3−/[Fe(CN)6]
4− signal than 
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that of cisplatin itself. 
 
Figure 2.6: (a). CV curves of [Fe(CN)6]
3−/[Fe(CN)6]
4− tested by the bare Au 
electrode(—) and the ssDNA-AuE (—). (b). CV curves of [Fe(CN)6]3-/[Fe(CN)6]4- 
tested by the ssDNA-AuE after 8 hours treatment by 500 uM CDDP (—), 500 uM 
CDDP+1 mM TMPD (—). (—) bare Au electrode, (—) ssDNA-AuE. (c). the Ipc of 
[Fe(CN)6]
3−/[Fe(CN)6]
4− tested by the ssDNA-AuE treated by 500 uM CDDP(■), 500 
uM CDDP+1 mM TMPD(●) over time. (d). the △Ep of [Fe(CN)6]3−/[Fe(CN)6]4− 
tested by the ssDNA-AuE treated by 500 uM CDDP(■), 500 uM CDDP+1 mM 
TMPD(●) over time. 
 
Two explanations can account for the [Fe(CN)6]
3−/[Fe(CN)6]
4− signal recovery. 
First one is the binding of cisplatin on DNA strand. As it mentioned in Chapter 1, 
cisplatin can bind on DNA bases. Upon the binding of cisplatin on DNA bases, the 
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chloride anion in cisplatin is replaced by a neutral base molecule, which adds a positive 
charge to the DNA strand and decreases the negative charge on the DNA strand, and 
therefore the electrode surface. So the electrical property change due to the binding 
could recover the [Fe(CN)6]
3−/[Fe(CN)6]
4−electrochemical response. Also, DNA strand 
break could be the other reason for the recovery of [Fe(CN)6]
3−/[Fe(CN)6]
4− signal. As 
it demonstrated in Lu’s work9, DNA double strand break was observed in gel 
electrophoresis experiment. It indicated that DNA strand break can be directly induced 
by cisplatin instead of being a product of intermediate step during intracellular repair 
process. Upon the break of DNA strand, the phosphate backbone will leave from the 
electrode surface, leading to a lower density of negative charges on the electrode surface, 
so the [Fe(CN)6]
3−/[Fe(CN)6]
4− signal will be recovered.  
To explain the interaction between cisplatin and DNA strand, elementary analysis 
was preformed to gain the information about the DNA modified surfaces. Figure 2.7 
shows the XPS spectra of N, P, Au and Pt on the DNA modified Au surface with and 
without cisplatin treatment. The presence of N and P is observed on the surface (figure 
2.7a and b). It is the best evidence of successful DNA modification because these two 
elements cannot be introduced during sample preparation and treatment. Au signal was 
acquired to act as a reference. Pt signal was acquired to show the adsorption of cisplatin 
on DNA strands.  
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Figure 2.7: High-resolution XPS spectra of the N 1s (a), P 2p (b), Au 4f (c) and Pt 4f 
(d) regions for the ssDNA modified surface with and without cisplatin treatment 
After taking the relative sensitivity factor into account, the percentages of these 
four elements on the surface were calculated and shown in table 2.1.  
Table 2.1: percentages of each element on the DNA modified Au surfaces with and 
without cisplatin treatment.  
element Without cisplatin treatment With cisplatin treatment 
N 18.91% 
 
23.33% 
 
P 6.77% 5.73% 
 
Au 73.71% 
 
67.00% 
 
Pt 0.62% 
 
3.94% 
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The decrease of the Au 4f intensity by 6.71 % shows that the surface was covered 
by more other elements. Meanwhile, it is observed that the signal intensities of N 1s 
and Pt 4f increased by 4.42 % and 3.32 %, suggesting the binding of cisplatin onto the 
ssDNA on the Au surface. The P 2p intensity decreased by 1.04 %. Because there is no 
P element in the structure of cisplatin, the same degree of decrease as Au 4f signal was 
expected for that of P 2p. So the expected percentage of P element on the surface after 
cisplatin treatment should be 6.15 %, 0.42 % higher than the actual value. This 
difference suggested that some P atoms left the surface after the cisplatin treatment. If 
looking into the N percentage change, the expected N percentage donated from DNA 
strands should be 17.19 % (the same degree of decrease as Au 4f signal). Assuming two 
N atoms along with one Pt are attached to the DNA strands for the binding of one 
cisplatin molecule, the expected N percentage should be 23.83 % (17.19 % + 2*3.32 %), 
0.50 % higher than the actual value. As a result, the percentage differences of N and P 
between the expected and the actual values suggested that a few DNA strands left the 
surface after cisplatin treatment. In addition, a shift of N and P signal to lower binding 
energy was observed after the cisplatin treatment. It was reported that a similar shift to 
higher binding energy was observed for surfaces modified with ssDNA from lower to 
higher density79. So the shift to lower binding energy observed in this project suggested 
a lower density of DNA covered surface, and therefore suggested the DNA strand break 
after cisplatin treatment. From the above, it could be concluded that both cisplatin 
binding and DNA strand break contributed to the recovery of [Fe(CN)6]
3−/[Fe(CN)6]
4− 
signal.  
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2.3.4 Conclusion 
In summary, the Au electrode was successfully modified by using ssDNA through 
Au-thiol chemistry. By using the redox signal from an indicator, 
[Fe(CN)6]
3−/[Fe(CN)6]
4−, the ssDNA-AuE was successfully characterized. Lower 
current response of [Fe(CN)6]
3−/[Fe(CN)6]
4- was observed at the ssDNA-AuE 
compared with bare Au electrode, due to the repulsive force between this redox pair 
and the DNA strands on the electrode surface. After the ssDNA-AuE was treated by 
using cisplatin, the recovery of the [Fe(CN)6]
3−/[Fe(CN)6]
4− redox signal indicated the 
interaction between ssDNA and cisplatin. Elementary analysis suggested that both the 
binding of cisplatin on DNA strand and DNA strand break contributed to the signal 
recovery. More interestingly, stronger [Fe(CN)6]
3−/[Fe(CN)6]
4− signal was recovered on 
the ssDNA-AuE treated by the combination of cisplatin and TMPD than that treated by 
cisplatin only, showing that this method is sensitive enough to detect the enhanced 
effect caused by the electron donor TMPD and could be applied to study the 
effectiveness of the cisplatin based combination chemotherapy.  
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Chapter 3  
Design of the carbon nanomaterials acting as a 
new generation of electron donor 
3.1 Introduction 
As it mentioned in Chapter 1, CNMs can act as electron donors due to their 
electron-rich delocalized π bond. Carrying the basic structure for all CNMs, graphene 
became the most interesting material since the first day when it was discovered. In 
Chapter 1, we predicted that graphene is able to donate electrons to cisplatin. Therefore, 
a strong electron transfer reaction from graphene to cisplatin is expected, thereby 
boosting the efficacy of this famous anticancer drug. The modified Hummer’s method 
is a common protocol for the synthesis of GO. The GO produced by this method has 
good solubility in daily used laboratory solvents. However the electronic property of 
graphene was heavily destructed due to the harsh oxidation environment during the 
synthesis process. Therefore reduction treatment is needed to recover the electron-rich 
structure to make the electron transfer reaction from graphene to cisplatin possible. 
Graphene and its derivatives have potential applications in many areas such as 
optical, composite, energy storage and biological materials. In order to use graphene in 
biological area, the priority is to increase CNMs’ solubility and biocompatibility in the 
physiological environment. As it mentioned in Chapter 1, this problem can be solved 
by using suitable functionalization, such as grafting hydrophilic polymers.  
In this chapter, GO is synthesized through the modified Hummer’s method, 
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followed by the reduction treatment using hydrazine. The Characterization of GO and 
rGO was done by using atomic force microscopy (AFM), UV-vis spectroscopy and 
Fourier transform infrared spectroscopy (FT-IR). Afterwards, the rGO was 
functionalized using amine terminated PEG through carbodiimide chemistry. Finally, 
the electron donating capability of the PEGylated rGO was tested by the 
electrochemical methods designed in Chapter 2. 
3.2 Materials and method 
Chemical and reagents: graphite flakes (100 mesh), potassium persulfate, 
Hydrazine monohydrate and Poly(ethylene glycol) bis(amine) (MW=3000) were 
purchased from Sigma-Aldrich. Phosphorus pentoxide was purchased from EMD. 1-
Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) was purchased from 
GBiosciences. N-Hydroxysuccinimide (NHS) was purchased from Alfa Aesar. 
Synthesis of GO: GO was synthesized through the modified Hummer’s method 
as it reported before30. Briefly, graphite flakes were pre-oxidized by using K2S2O8, P2O5 
and concentrated H2SO4. Afterwards, the pre-oxidized product was subject to extensive 
oxidation following Hummer’s method. The final concentration of the as-synthesized 
GO was determined after filtration, weighing and re-dissolving, to be 5 mg/ml. 
Reduction of GO: the as-synthesized GO was reduced using hydrazine as it 
reported before36. This method can maintain the carboxylic acid groups in GO, while 
recover the other oxidative defects. To be brief, the GO solution was diluted to a 
concentration of 2 mg/ml. The diluted solution (7.5 ml) was added to a water solution 
(7.5 ml) including 1.4 mg/ml hydrazine and 11.2 mg/ml ammonium, followed by 1 
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hours reaction in a water bath at 95 ℃. The resulted dispersion was dialyzed using 
Milli-Q water to remove the excess hydrazine in the solution for 5 days with every 4 
hours water change. .  
UV-vis spectroscopy of GO and rGO: 75 ug/ml GO solution and 25 ug/ml rGO 
solutions were prepared by using the stock solutions GO and rGO and Milli-Q water. 
The UV-vis spectra were recorded from 200 nm to 900 nm using a spectrophotometer. 
FT-IR and Raman characterization of GO and rGO: 2 ml of 1 mg/ml GO and 
2 ml of 1 mg/ml rGO solutions were vacuum filtrated by using PC membranes (25 mm 
diameter, 0.1 um pore size; Whatman), followed by 5 ml Milli-Q water rinse for three 
times. The as-prepared GO and rGO membranes were dried overnight in a 70 ℃ oven 
for FT-IR characterization. Part of the GO and rGO were peeled off from the PC 
membranes and finely ground with KBr separately (Sigma Aldrich) and compressed 
into two thin pallets. The FT-IR spectra of GO and rGO were collected by using a 
Bruker Tensor 37 FTIR spectrometer from 4000 cm-1 to 600 cm-1. The left GO and 
rGO membranes were characterized using a Horiba Jobin Yvon LabRAM HR 800 
Raman spectrometer with a 532 nm excitation laser. The Raman spectra were recorded 
from 1000 cm-1 to 2000 cm-1. 
Atomic Force Microscopy (AFM) of GO and rGO: GO and rGO solutions were 
diluted until their color almost disappear by using HPLC grade ethanol. The diluted 
solutions were drop casted on fresh cleaved mica surfaces respectively for three minutes, 
followed by blow-drying using high pure nitrogen gas. The AFM images were collected 
by using a Nanoscope MultiMode™ AFM instrument (Veeco) in the taping mode. A 
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silicon probe with a resonant frequency of 300 kHz was used. 
PEGylation of rGO: rGO was functionalized by using linear amine terminated 
PEG through carbodiimide chemistry. Briefly, 10 ml of 1mg/ml rGO solution was 
added to 5 mL of 2-(N-morpholino)ethanesulfonic acid (MES) buffer solution 
containing 20 mg amine terminated linear PEG and excess EDC as well as NHS. The 
mixed solution was kept stirring overnight at room temperature, followed by three days 
dialysis with every 4 hours water change. The dialyzed solution was centrifuge filtered 
and re-dissolved until a final concentration of 1.5 mg/ml was achieved and stored for 
future use.  
Solubility test of GO, rGO and PEG-rGO: 200 ul 1 mg/ml GO, rGO and PEG-
rGO solutions were mixed with 800 ul PBS (16 mM K2HPO4, 150 mM NaCl, pH 7.2) 
buffer respectively. All solutions were kept at room temperature for 1 hour and 
centrifuged at 14000 rpm for 10 mins.  
Electrochemical study of PEG-rGO’s effect on the interaction between 
cisplatin and DNA strand: a mixture of 500 uM (0.15 mg/ml) cisplatin and 1.3 mg/ml 
PEG-rGO were prepared by using the stock cisplatin solution and PEG-rGO solution. 
The CV curves of 5 mM [Fe(CN)6]
3−/[Fe(CN)6]
4− were recorded by using the ssDNA-
AuE after the treatment in the prepared solution for 0, 2, 4, 8 and 19 hours.  
Effect of PEG-rGO on the interaction between cisplatin and DNA strand: two 
solutions containing 500 uM (0.15 mg/ml) cisplatin, 500 uM dGMP and different 
concentration (0.15 mg/ml or 0.75 mg/ml) of PEG-rGO were prepared by using the 
stock solutions and 0.5 M acetate buffer. Two solutions containing 500 uM (0.15 mg/ml) 
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cisplatin and different concentration of PEG-rGO (0.15 mg/ml or 0.75 mg/ml) were 
prepared using the stock solutions and 0.5 M acetate buffer, to collect the background 
currents. CV curves of the two solutions containing dGMP were recorded after 0, 5, 10, 
24 and 48 hours incubation, using the same GCE and the potentiostat in Chapter 2. The 
background CV current was recorded by using the two solutions without dGMP after 0, 
5, 10, 24 and 48 hours incubation. 
Clonogenic assay of HeLa cells: Reasonable number of HeLa cells were seeded 
in 5 six-well plates (Thermo scientific) respectively and treated by 0.1, 0.5, 1, 2 and 5 
uM cisplatin and 0.1, 0.5, 1, 2 and 5 uM cisplatin plus 10ug/ml PEG-rGO for 2 hours 
(each treatment containing three parallel experiments). Following this, the treated cells 
were incubated for 7 days and dyed by crystal purple. The cell viability in each group 
was determined based on the colonies formed after the incubation.  
3.3 Results and Discussion 
GO and rGO were successfully synthesized as shown in Figure 3.1a and b. the 
color of rGO is more black than that of GO, owing to the removal of the defects from 
the GO structure after reduction. This change can be theoretically shown by the UV-vis 
absorption spectra of GO and rGO (Figure 3.1c). Compared with GO, the absorption 
peak of rGO shifted from 227 nm to 262 nm, indicating the restored aromatic C=C bond 
after reduction36. At the same time, the shoulder peak around 300 nm in the spectrum 
of GO, which can be attributed to the transitions of C=O bond93, disappeared in that of 
rGO, demonstrating a decreased oxygen level in rGO structure. Both these changes 
showed that the GO was effectively reduced and the electronic property of graphene 
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was recovered.   
 
Figure 3.1: as-synthesized (a) GO solution and (b) rGO solution (c) UV-vis absorption 
spectra of GO and rGO. 
Figure 3.2a and b are the AFM images of as-synthesized GO and rGO sheets on 
fresh cleaved mica substrates. The lateral size of the as-synthesized GO ranges from 
hundreds of nanometers to several micrometers. The thickness of the GO is ~1.1 nm, 
while rGO is ~0.7 nm as shown in Figure 3.2c and d. Compared with GO, the thickness 
of rGO is ~0.4 nm thinner. However, it was reported that the oxygen-containing 
functionalized groups are sized in around 100 picometers range94. So the removal of 
these oxygen-containing groups cannot straightforwardly explain the observed decrease 
in the height profile. However, it is well-known that for all AFM experiments conducted 
in air environment, a thin layer of water always exists on the sample. So the removal of 
the hydrophilic oxygen-containing groups can potentially decrease the amount of the 
thin layer of water on rGO, therefore making the tested rGO thickness much thinner 
than that of GO. 
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Figure 3.2: AFM images of (a) GO and (b) rGO. (c) Height profile along the line drawn 
in (a), showing the thickness of GO (~1.1 nm). (d) Height profile long the line drawn 
in (b), showing the thickness of rGO (~0.7 nm). 
The Raman spectra of GO and rGO are shown in Figure 3.3. The characterization 
peaks of GO and rGO are respectively the D band at ~1350 cm-1 and the G band at ~ 
1590 cm-1. It is reported that the D band arises from defect mediated zone-edge (near 
K-point) phonons, whereas the G band is attributed to the doubly degenerate E2g 
mode at the Brillouin zone center30. The intensity of the D band /G band ratio (ID/IG) is 
widely used for determining the degree of defect in graphene-related materials. From 
the Raman spectra of GO and rGO, it is shown that the ID/IG increased from 0.86 for 
GO to 1.07 for rGO, indicating a decrease in the average size of the sp2 domains upon 
the reduction of GO. This change is typical for hydrazine reduced GO and can be 
explained, for the reduced GO, new graphene-like domains created after the reduction 
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are smaller in size than the ones present in the GO films before the reduction, but more 
numerous in number. As a result, the electronic property of graphene is still restored, 
even though the ID/IG increases in Raman spectra. 
Stabilities of GO, rGO and PEG-rGO in physiological environment were studied 
by using the saline solution. After mixed with PBS buffer and treated by the high-speed 
centrifugation, the status of all the three samples are shown in Figure 3.4. Both GO and 
rGO have very poor stabilities after mixed with PBS buffer, while PEG-rGO is much 
more stable after all the treatment. This result showed the effectiveness the PEGylation, 
and meanwhile suggested the success of the PEG functionalization.  
 
Figure 3.3: Raman spectra of GO and rGO. 
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Figure 3.4: The solutions of GO, rGO and PEG-rGO (from left to right) after 1 hour 
of PBS buffer treatment and 10 mins of centrifugation.  
After the fabrication of the stable PEG-rGO, the electrochemical study of PEG-
rGO’s effect on the interaction between cisplatin and DNA strand was conducted by 
using the methods developed in Chapter 2. The recovery of the [Fe(CN)6]
3−/[Fe(CN)6]
4− 
signal was recorded after the ssDNA-AuE was treated in a solution containing 500 uM 
cisplatin and 1.3 mg/ml PEG-rGO for 8 hours (Figure 3.5a). Compared with 500 uM 
cisplatin only, the combination of 500 uM cisplatin and 1.3 mg/ml PEG-rGO did not 
show much noticeable difference in the change of either the Ipc or the △Ep value. 
Figure 3.5b shows that the Ipc of [Fe(CN)6]
3−/[Fe(CN)6]
4− tested by ssDNA-AuE treated 
with 500 uM cisplatin only and cisplatin in combination with 1.3 mg/ml PEG-rGO over 
time. The nearly identical Ipc at various time points showed that the PEG-rGO basically 
had no effect on the interaction between cisplatin and DNA strand.  
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Figure 3.5: (a). CV curves of [Fe(CN)6]
3−/[Fe(CN)6]
4− tested by the bare Au 
electrode(—), the ssDNA-AuE (—), CV curves of [Fe(CN)6]3-/[Fe(CN)6]4- tested by 
ssDNA-AuE after 8 hours treatment by 500 uM CDDP (—), 500 uM CDDP+1 mM 
TMPD (—) and 500 uM CDDP + 1.3 mg/ml PEG-rGO. (b). the Ipc of 
[Fe(CN)6]
3−/[Fe(CN)6]
4− at various time points after ssDNA-AuE treated by 500 uM 
CDDP(■), 500 uM CDDP+1 mM TMPD(●) and 500 uM CDDP+1.3 mg/ml PEG-
rGO(▲). 
In addition, the electrochemical method using the oxidation signal of G base as an 
indicator was also applied to study the effect of PEG-rGO on the interaction between 
DNA and cisplatin. In this experiment, the dGMP oxidation peak exhibited nearly 
identical trends over time, no matter in the presence of PEG-rGO or not (Figure A.1), 
supporting the results from the ssDNA-AuE electrochemistry.  
Figure 3.6 shows the survival percentage of HeLa cells after treated by cisplatin 
only and cisplatin in combination with PEG-rGO in the clonogenic assay. Compared 
with the groups treated by cisplatin only, the groups treated by cisplatin in combination 
with PEG-rGO didn’t show any noticeable enhanced cell killing, which is consistent 
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with the results got from the electrochemical study. So above all, it could be concluded 
that PEG-rGO, not as expected, cannot enhance the efficacy of cisplatin.  
 
Figure 3.6: Clonogenic assay of HeLa cells with treatment of cisplatin alone and in 
combination with PEG-rGO. 
 
It is reported that Pt nanoparticles (Pt NPs) can be produced from H2PtCl6 and GO 
by heat or reducing agents, such as NaBH4
95,96. So after the electron transfer reaction 
between cisplatin and rGO, it is possible that some cisplatin radicals can be adsorbed 
on the PEG-rGO nanosheets, preventing the leaving of these radicals, and therefore the 
attacking to DNA strands. In addition, the absence of electron transfer reaction between 
cisplatin and PEG-rGO could be another reason for the lack of enhanced effect, so very 
similar results were observed no matter in the presence of PEG-rGO or not. Therefore, 
future work is needed to confirm why PEG-rGO is not able to enhance the efficiency 
of cisplatin, so that a better design can be made. 
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3.4 Conclusion 
In conclusion, rGO was successfully fabricated through the modified Hummer’s 
method followed by hydrazine reduction. The UV-vis spectra and AFM images showed 
that, after the reduction, most of the oxygen containing groups were removed from the 
GO surface, and the electronic property of graphene was recovered. Furthermore, rGO 
was successfully functionalized by linear PEG using carbodiimide chemistry and the 
PEGylation was verified by the solubility test. The effect of PEG-rGO on the interaction 
between cisplatin and DNA was investigated, using the electrochemical methods 
described in Chapter 2 along with the Clonogenic assay. None of these experiments 
showed noticeable enhanced cisplatin efficiency when combining cisplatin and PEG-
rGO. The formation of Pt NPs or the absence of electron transfer reaction between 
cisplatin and PEG-rGO could be the reason for the lack of enhanced cisplatin efficiency. 
Therefore, future work is needed to make graphene an effective electron donor.  
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Chapter 4 
Summary 
Cisplatin is an anticancer chemotherapy drug used for treating a wide range of 
cancers. The hydrolysis mechanism is long believed the initial action of this drug. So 
based this mechanism, over 3000 of cisplatin analogues were synthesized to reduce the 
side effect and increase the treatment efficacy. However only oxaliplatin and 
carboplatin were approved by FDA, suggesting that the hydrolysis mechanism might 
not be the right principle behind cisplatin toxicity. Recently, by using a femtosecond 
time-resolved laser spectroscopy, an electron transfer reaction mechanism of cisplatin 
and DNA was proposed. Based on this mechanism, it is observed that the combination 
of cisplatin and an electron donor can dramatically increase the efficacy of cisplatin, 
opening a new gate for the design of cisplatin based combination chemotherapy.   
As the most popular material in the past decade, graphene attracted tons of 
attention because of its unique electronic and mechanical properties. The delocalized π 
bond structure makes graphene a potential electron donor, making it possible to 
establish a new generation of combination therapy by using cisplatin and CNMs.  
The electrochemical method is a powerful tool to get DNA related information 
such as DNA base damage, DNA strand break, DNA sequencing and DNA 
hybridization. In Chapter 2, two electrochemical methods were designed, using the 
redox signal of DNA bases, and an indicator species along with the ssDNA-AuE, to 
study the DNA damage. In the first method, the interaction between cisplatin and dGMP 
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was characterized and studied by the decrease in the dGMP oxidation peak. However, 
by using this method, the combination of cisplatin and TMPD didn’t lead to faster or 
more pronounced decrease in the dGMP oxidation peak compared with cisplatin itself, 
probably due to the autoionization of TMPD in water. In the second method, ssDNA-
AuE was fabricated and the interaction between cisplatin and ssDNA was monitored by 
the redox signal change of a pair of indicator, [Fe(CN)6]
3-/[Fe(CN)6]
4-. Briefly, 
compared with the bare Au electrode, decrease of the [Fe(CN)6]
3-/[Fe(CN)6]
4- redox 
signal was observed at the ssDNA-AuE, due to the repulsive force between the ssDNA 
and the negatively charged indicator. After the ssDNA-AuE was treated by cisplatin, 
the redox signal of [Fe(CN)6]
3-/[Fe(CN)6]
4- recovered, suggesting that cisplatin reduced 
the repulsive force between this indicator and the ssDNA. Elementary analysis 
confirmed that both cisplatin binding and DNA strand break contributed to the recovery 
of [Fe(CN)6]
3-/[Fe(CN)6]
4- signal. More interestingly, stronger [Fe(CN)6]
3−/[Fe(CN)6]
4− 
signal was recovered on the ssDNA-AuE treated by the combination of cisplatin and 
TMPD than that on the same electrode treated by cisplatin only, showing that this 
method is sensitive enough to detect the enhanced effect caused by TMPD and could 
be applied to study the effectiveness of the cisplatin based combination chemotherapy.  
In chapter 3, rGO was synthesized through the modified Hummer’s method 
followed by hydrazine reduction. UV-vis and AFM characterization showed that the 
oxygen containing groups were successfully removed from GO nanosheets, and the 
electronic property of graphene was recovered. Furthermore, rGO was successfully 
functionalized by linear PEG using carbodiimide chemistry and the PEGylation was 
51 
 
verified by the solubility test. After the fabrication, the effect of PEG-rGO on the 
interaction between cisplatin and DNA was investigated, by using the methods designed 
in Chapter 2 as well as the in vitro experiment. However, all experiment results point 
to the conclusion that PEG-rGO has no noticeable impact on improving cisplatin 
efficacy. The formation of Pt NPs or the absence of electron transfer reaction between 
cisplatin and PEG-rGO could be the reason why no enhanced cisplatin efficacy can be 
observed. Therefore, future work is needed to make graphene an effective electron 
donor.  
Our study, for the first time, used the intrinsic DNA signal and the signal from 
indicator species along with the ssDNA-AuE to detect DNA damage caused by cisplatin. 
DNA base damage and DNA strand damage were respectively detected by these two 
methods. In addition, our work for the first time designed a CNM and cisplatin based 
combination chemotherapy, which can be a reference for similar future research.  
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Chapter 5 
Future work 
Even though two electrochemical methods were designed to detect DNA damage, 
some changes could be done to improve them. For PEG-rGO, because no enhanced 
DNA damage or cell killing was observed when combining with cisplatin, the design 
of an effective graphene based material which can act as an electron donor still need to 
continue.  
First, in the electrochemical method using the dGMP oxidation signal as an 
indicator, the combination of cisplatin and TMPD didn’t lead to faster or more 
pronounced decrease in the dGMP oxidation peak compared with cisplatin itself. The 
instability of TMPD in aqueous solution makes it hard to tell whether it is the method 
itself or the autoionization of TMPD causing the failure to observe the enhanced dGMP 
decrease. To verify the effectiveness of this method, it is important to rule out the 
interference from TMPD autoionization. So instead of water, some other non-aqueous 
solvents can be used to prepare the experiment solutions to avoid the occurrence of 
TMPD autoionization. The eligible solvent should meet the requirements including, the 
ability to dissolve cisplatin, TMPD, DNA bases (or their derivatives) and suitable 
electrolyte, and a low binding energy of solvated electron, so that TMPD can be 
stabilized in the solvent. Alternatively, replacing TMPD by some other electron donors 
which are stable in aqueous solutions is also a good choice to rule out the interference 
from TMPD autoionization. 
53 
 
Second, it is well-known that DNA double strand break is important to induce cell 
death. So if our DNA modified electrode can be used for detecting DNA double strand 
break, it could be more useful for testing the efficacy of cisplatin or some other 
anticancer drugs compared with the current design. To realize this detection, we can 
hybridize the ssDNA on the Au electrode by its complementary DNA, so that a double-
stranded DNA modified surface can be generated. By recording the similar 
electrochemical signal change described in this project and XPS data, the information 
about DNA double strand break could be collected. Furthermore, DNA strands with 
unique sequence, for example G base-rich DNA strand, can be used to improve the 
sensitivity of the detection. 
Finally, the reason why PEG-rGO cannot enhance cisplatin efficacy should be 
uncovered so that an effective graphene based electron donor can be designed. To 
confirm the formation of Pt NPs, elementary analysis can be used. Briefly, a graphene 
covered surface can be prepared by drop casting, or some other method such as 
chemical vapor deposition, followed by soaking in a cisplatin solution for certain time. 
If the Pt signal can be detected on the surface, the formation of Pt NPs will be confirmed. 
If no Pt signal can be detected on the surface, it might imply that there is no electron 
transfer reaction between cisplatin and PEG-rGO. In the case of the second situation, 
some functionalization will be needed to make graphene an effective electron donor. 
For example, some electron donating molecules can be linked on the structure of 
graphene nanosheets, such as porphyrin or oligothiophene97,98. It is expected that 
electrons can transfer from the electron donating molecule either directly to cisplatin or 
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to graphene at first, then cisplatin. In addition, we can also dope graphene using some 
active metal atoms, to slightly change its electronic property, therefore making it a more 
effective electron donor compared with the bare graphene.  
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Appendix 
FT-IR and Raman characterization of GO and rGO: 
 
Figure A.1: FT-IR spectra of GO and rGO. 
For the FT-IR spectra, the C=C absorption in rGO shifted to a lower wavenumber 
than that in GO. In addition, the C-O absorption in the spectrum of GO disappeared in 
that of rGO, indicating the leaving of hydroxyl and epoxy groups from the surface of 
GO.  
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Effect of PEG-rGO on the interaction between cisplatin and DNA base: 
 
Figure A.2: Background subtracted CV curves of 500 uM dGMP mixed with 500 uM 
CDDP and (a) 0.15 mg/ml, (b) 0.75 mg/ml PEG-rGO at various time points. Scan rate: 
20 mV/s. (c) Oxidation peak value of 500 uM dGMP mixed with 500 uM CDDP (■), 
500 uM CDDP+ 0.15 mg/ml PEG-rGO (●) and 500 uM CDDP+ 0.75 mg/ml PEG-rGO 
(▲) over time. (d) Normalized oxidation peak value of 500 uM CDDP (■), 500 uM 
CDDP+ 0.15 mg/ml PEG-rGO (●) and 500 uM CDDP+ 0.75 mg/ml PEG-rGO (▲) 
over time. 
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